Torrent Pharma’s Shelcal 500 fails CDSCO quality test

27 Sep 2024 , 02:40 PM

Torrent Pharmaceuticals’ stock opened with slight losses on September 27 after its product, Shelcal 500, failed a quality test conducted by the Central Drug Standards Control Organisation (CDSCO).

The pharma firm has denied the findings, stating that a batch of Shelcal 500 medicine that failed the CDSCO test was not made by the company and is ‘spurious.’ CDSCO recently warned that more than 50 medications were ‘not of normal quality’, creating safety concerns.

In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market. An evaluation was carried out to ensure the authenticity of the CDSCO sample, according to Torrent.

Torrent stated that it had introduced QR codes revealing batch production details to ensure authenticity, which was discovered lacking in Shelcal’s seized samples. Torrent has already filed its response and assessment report to CDSCO.

Popular medications such as antacid Pan D, calcium supplement Shelcal, anti-diabetic treatment Glimepiride, and high blood pressure pill Telmisartan are among those listed as “not of standard quality” (NSQ).

At around 12.12 PM, Torrent Pharma was trading 0.33% lower at ₹3,401.10 per piece, against the previous close of ₹3,412.30 on NSE. The counter touched an intraday high and low of ₹3,445.20, and ₹3,396, respectively.

For feedback and suggestions, write to us at [e-mail]